CA3179161A1 - Compositions therapeutiques comprenant des composes de n,n-dimethyl tryptamine deuteree ou partiellement deuteree - Google Patents

Compositions therapeutiques comprenant des composes de n,n-dimethyl tryptamine deuteree ou partiellement deuteree Download PDF

Info

Publication number
CA3179161A1
CA3179161A1 CA3179161A CA3179161A CA3179161A1 CA 3179161 A1 CA3179161 A1 CA 3179161A1 CA 3179161 A CA3179161 A CA 3179161A CA 3179161 A CA3179161 A CA 3179161A CA 3179161 A1 CA3179161 A1 CA 3179161A1
Authority
CA
Canada
Prior art keywords
compound
dimethyltryptamine
deuterated
composition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3179161A
Other languages
English (en)
Other versions
CA3179161C (fr
Inventor
Peter RANDS
Tiffanie BENWAY
Zelah JOEL
Marie LAYZELL
Ellen James
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybin Uk Ltd
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2020/065244 external-priority patent/WO2020245133A1/fr
Priority claimed from US17/108,679 external-priority patent/US20220168274A1/en
Priority claimed from GBGB2018950.2A external-priority patent/GB202018950D0/en
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Priority claimed from PCT/EP2021/060750 external-priority patent/WO2021116503A2/fr
Publication of CA3179161A1 publication Critical patent/CA3179161A1/fr
Publication of CA3179161C publication Critical patent/CA3179161C/fr
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un composé N,N-diméthyltryptamine deutéré ou une pluralité de composés N,N-diméthyltryptamine deutérés destinés à être utilisés en thérapie, sélectionnés parmi les composés N,N-diméthyltryptamine, les composés a-protio, a-deutéro-N,N- diméthyltryptamine, les composés a,a-dideutéro-N,N-diméthyltryptamine, et des sels pharmaceutiquement acceptables de ces composés, préférablement le composé N,N-diméthyltryptamine deutéré présentant une demi-vie accrue par rapport au composé N,N-diméthyltryptamine non deutéré. En particulier, l'invention concerne un composé de formule I, ou un sel pharmaceutiquement acceptable de celui-ci; (I) le rapport deutérium:protium dans le composé étant supérieur à celui trouvé naturellement dans l'hydrogène; chaque R1 étant sélectionné indépendamment parmi H et D; R2 étant sélectionné parmi CH3 et CD3; R3 étant sélectionné parmi CH3 et CD3; et chaque yH étant sélectionné indépendamment parmi H et D. Des procédés de synthèse de composés de la présente invention, et des procédés d'utilisation de telles compositions dans le traitement de troubles psychiatriques ou neurologiques, tels que le trouble dépressif majeur, sont également fournis.
CA3179161A 2020-06-02 2021-04-23 Compositions therapeutiques comprenant des composes de n,n-dimethyl tryptamine deuteree ou partiellement deuteree Active CA3179161C (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
EPPCT/EP2020/065244 2020-06-02
GB2008303.6 2020-06-02
PCT/EP2020/065244 WO2020245133A1 (fr) 2019-06-03 2020-06-02 Compositions thérapeutiques comprenant des composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
US16/890,664 2020-06-02
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
US16/890,664 US11771681B2 (en) 2019-06-03 2020-06-02 Therapeutic compounds
GB2018955.1 2020-12-01
GB2018950.2 2020-12-01
US17/108,679 US20220168274A1 (en) 2020-12-01 2020-12-01 Parenteral Formulation
US17/108,938 2020-12-01
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GBGB2018950.2A GB202018950D0 (en) 2020-12-01 2020-12-01 Parenteral formulation
US17/108,679 2020-12-01
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
GB2103981.3 2021-03-22
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds
US17/208,583 2021-03-22
PCT/EP2021/060750 WO2021116503A2 (fr) 2020-06-02 2021-04-23 Composés deutérés

Publications (2)

Publication Number Publication Date
CA3179161A1 true CA3179161A1 (fr) 2021-06-17
CA3179161C CA3179161C (fr) 2023-10-31

Family

ID=84083617

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3179161A Active CA3179161C (fr) 2020-06-02 2021-04-23 Compositions therapeutiques comprenant des composes de n,n-dimethyl tryptamine deuteree ou partiellement deuteree

Country Status (10)

Country Link
JP (1) JP7288154B2 (fr)
KR (1) KR102589605B1 (fr)
CN (1) CN116056763B (fr)
AU (1) AU2021204158B2 (fr)
CA (1) CA3179161C (fr)
ES (1) ES2928395T3 (fr)
IL (1) IL298541B1 (fr)
MX (1) MX2022014900A (fr)
NZ (1) NZ794833A (fr)
PL (1) PL3902541T3 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007310949A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
EP3713568A1 (fr) * 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20230281T1 (hr) * 2019-11-07 2023-04-28 Small Pharma Ltd Postupak sinteze

Also Published As

Publication number Publication date
PL3902541T3 (pl) 2022-11-14
IL298541A (en) 2023-01-01
ES2928395T3 (es) 2022-11-17
CN116056763A (zh) 2023-05-02
KR102589605B1 (ko) 2023-10-13
CA3179161C (fr) 2023-10-31
JP2023520256A (ja) 2023-05-16
MX2022014900A (es) 2023-03-27
AU2021204158B2 (en) 2023-03-02
CN116056763B (zh) 2024-03-05
NZ794833A (en) 2023-03-31
JP7288154B2 (ja) 2023-06-06
KR20230007547A (ko) 2023-01-12
AU2021204158A1 (en) 2023-01-05
IL298541B1 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
EP3902541B1 (fr) Compositions thérapeutiques comprenant des composés de n,n-dimethyltryptamine deutérés ou partiellement deutérés
US11471417B2 (en) Deuterated N,N-dimethyltryptamine compounds
AU2020381103B2 (en) Compounds
CA3104072C (fr) Compositions de substances de medicament comprenant de la n,n-dimethyltryptamine
US11773062B2 (en) Deuterated compounds
WO2022117359A1 (fr) Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
AU2021204158B2 (en) Deuterated compounds
GB2605144A (en) Deuterated compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930

EEER Examination request

Effective date: 20220930